MannKind Corporation (NASDAQ:MNKD) Posts Revenues Of $15.1 Million In Q2 2020

MannKind Corporation (NASDAQ:MNKD) reported revenues of $7 million from the sale of Afrezza and $8.1 million from the services/ collaboration segment.

CEO of MannKind, Michael Castagna said its team put in significant efforts to boost the sales of Afrezza despite hardships imposed by COVID-19 pandemic.

Adds Alejandro Galindo as CCO

MannKind added Alejandro Galindo as Chief Commercial Officer with effect from August 4, 2020. He brings a proven experience of over 25 years in consumer, energy, and healthcare industries. During his 6 years as VP Medtronic and President at Advanced Insulin Management Business Unit, Alejandro helped to achieve double-digit growth in revenues from diabetes division worldwide.

Before joining Medtronic, Alejandro worked for 9 years at GE Healthcare in emerging markets, global supply chain operations, strategic corporate development and other leadership roles. He holds MS, and MBA degrees.

Michael participates in a Fireside Chat

On August 11, 2020, Michael will participate in a chat at BTIG Virtual Biotechnology Conference. It also features fireside chat and virtual presentation on June 24, 2020, at LP VVIGF (Lytham Partners Virtual Investor Growth Conference). The management of MannKind will also take part in one-on-one meetings, virtually with investors on the same day.

Presents clinical studies outcome of insulin hormone

MannKind presented the clinical studies outcome of insulin hormone – Afrezza inhalation powder at 80th scientific sessions of ADA (American Diabetes Association) from June 12 to 16, 2020.

The company assessed the effective and safe dosing of Afrezza in people who have Type 1 diabetes during the comprehensive post hoc analysis. It demonstrated weight loss in type 2 diabetes patients administered with Afrezza compared to type 2 diabetes patients treated with mealtime insulin injection.

In a two year study treating the patients with Afrezza, significant changes are observed in FEV1.

The detailed studies provide support to the clinical safety and effectiveness of Afrezza and help to choose correct dosing for a favorable effect of the drug on the weight of a human body.

Afrezza, a dry powder form of insulin, is delivered to the patient using a portable and small inhaler before taking a meal. It quickly dissolves and enters the bloodstream to reduce blood sugar levels.